ReviewBioanalysis2012
Defining putative glycan cancer biomarkers by MS.
Review in Bioanalysis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 61 citations in OpenAlex.
- Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)-MS/MS.The Analyst · 2022Article
- Applications of Proteomics in Ovarian Cancer: Dawn of a New Era.Proteomes · 2022Review
- MS-based glycomics: An analytical tool to assess nervous system diseases.Frontiers in neuroscience · 2022Review
- Changes in the Expression of Renal Brush Border MembraneBiomolecules · 2021Article
- A nomogram based on glycomic biomarkers in serum and clinicopathological characteristics for evaluating the risk of peritoneal metastasis in gastric cancer.Clinical proteomics · 2020Article
- Glycosylation and glycan interactions can serve as extracellular machinery facilitating clathrin-independent endocytosis.Traffic (Copenhagen, Denmark) · 2019Review
- A carbon nanoparticles-based solid-phase purification method facilitating sensitive MALDI-MS analysis of permethylated N-glycans.Electrophoresis · 2018Article
- Clinical application of quantitative glycomics.Expert review of proteomics · 2018Review
- Mass spectrometry-based proteomics techniques and their application in ovarian cancer research.Journal of ovarian research · 2018Review
- Carbon Nanoparticles and Graphene Nanosheets as MALDI Matrices in Glycomics: a New Approach to Improve Glycan Profiling in Biological Samples.Journal of the American Society for Mass Spectrometry · 2018Article
- Comparison of the methods for profilingRSC advances · 2018Article
- Distinct cargo-specific response landscapes underpin the complex and nuanced role of galectin-glycan interactions in clathrin-independent endocytosis.The Journal of biological chemistry · 2018Article
- Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.Clinical and experimental medicine · 2017Article
- Quantitative Glycomics: A Combined Analytical and Bioinformatics Approach.Methods in enzymology · 2017Article
- Discovery of Non-invasive Glycan Biomarkers for Detection and Surveillance of Gastric Cancer.Journal of Cancer · 2017Article
- Quantitative LC-MS/MS Glycomic Analysis of Biological Samples Using AminoxyTMT.Analytical chemistry · 2016Article
- High-temperature LC-MS/MS of permethylated glycans derived from glycoproteins.Electrophoresis · 2016Article
- Parallel data acquisition of in-source fragmented glycopeptides to sequence the glycosylation sites of proteins.Electrophoresis · 2016Article
- Disease-specific IgG Fc N-glycosylation as personalized biomarkers to differentiate gastric cancer from benign gastric diseases.Scientific reports · 2016Article
- Serum glycoprotein-derived N- and O-linked glycans as cancer biomarkers.American journal of cancer research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
For decades, the association between aberrant glycosylation and many types of cancers has been shown. However, defining the changes of glycan structures has not been demonstrated until recently. This has been facilitated by the major advances in MS and separation science, which allows the detailed characterization of glycan changes associated with cancer. MS glycomics methods have been successfully employed to compare the glycomic profiles of different human specimens collected from disease-free individuals and patients with cancer. Additionally, comparing the glycomic profiles of glycoproteins purified from specimen collected from disease-free individuals and patients with cancer has also been performed. These types of glycan analyses employing MS or LC-MS allow the characterization of native, labeled and permethylated glycans. This review discusses the different glycomic and glycoproteomic methods employed for defining glycans as cancer biomarkers of different organs, including breast, colon, esophagus, liver, lung, ovarian, pancreas and prostate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.